Equities

NDT Pharmaceuticals Inc

NDTP:PKC

NDT Pharmaceuticals Inc

Actions
  • Price (USD)0.1989
  • Today's Change0.00 / 0.00%
  • Shares traded4.00
  • 1 Year change+19,785.00%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024 14:49 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NDT Pharmaceuticals, Inc. is a Canada-based company, which is focused on developing nutraceutical and pharmaceutical products utilizing intellectual property. The Company has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes a versatile and widely applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as Cell Armor.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2005
  • Employees1.00
  • Location
    NDT Pharmaceuticals IncSuite 809-4438 West 10Th AvenueVANCOUVER V6R 4R8CanadaCAN
  • Phone+1 (604) 689-4088
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aptorum Group Ltd431.38k-2.82m21.61m3.00--0.8238--50.10-0.9126-0.91260.09544.800.020830.363.88143,793.30-20.92-40.45-19.62-42.362.45-4.04-1,006.30-1,233.681.18--0.1694---66.712.3871.18---78.15--
Cumberland Pharmaceuticals, Inc.38.83m-8.42m21.71m91.00--0.7881--0.5592-0.596-0.5962.721.940.45420.88123.08426,654.70-9.83-7.03-14.07-9.5283.5479.95-21.65-17.641.21-37.100.3717---5.856.15-12.73---36.17--
Equillium Inc37.89m-12.13m23.34m44.00--1.11--0.6159-0.3476-0.34761.080.59830.6568--8.95861,227.30-21.02-46.81-39.66-57.36-----32.01-328.35----0.00--128.97--78.64--7.48--
Rapid Micro Biosystems Inc23.10m-51.90m25.85m193.00--0.2436--1.12-1.20-1.200.53552.480.15351.374.34119,663.20-34.49---38.20---22.59---224.73--5.62--0.0028--31.44--13.71------
Vyne Therapeutics Inc423.00k-28.50m26.59m10.00--0.3139--62.85-5.26-5.420.0215.830.0067----42,300.00-44.91-108.41-50.67-138.57-----6,738.06-1,907.10----0.00---11.11-47.5117.89------
Acasti Pharma Inc0.00-12.85m27.26m32.00--0.4415-----1.46-1.460.006.570.00-------16.86-31.68-17.45-33.95-------56,271.43---6.180.00------69.71---47.16--
NDT Pharmaceuticals Inc-100.00bn-100.00bn31.82m1.00--0.1776----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Aadi Bioscience Inc23.84m-68.83m34.38m75.00--0.38--1.44-2.55-2.550.88483.680.16920.60214.54267,865.20-48.86-50.25-56.39-56.1587.70---288.72-473.974.86--0.00--60.063.85-8.68--153.54--
Natural Alternatives International, Inc.120.20m-3.31m34.48m317.00--0.4125.690.2868-0.5646-0.564620.5313.560.80913.6312.77379,183.00-2.234.90-2.565.938.8515.98-2.753.802.44-2.710.09960.00-9.913.06-76.46-20.7427.08--
Cyclo Therapeutics Inc1.13m-19.39m34.91m8.00--57.23--30.99-1.03-1.030.05570.02130.20010.415511.12140,806.30-344.43-132.22-17,225.46-215.1791.0290.37-1,721.63-1,114.040.968--0.00---21.761.25-29.81---3.95--
Lexaria Bioscience Corp404.72k-5.44m37.81m5.00--5.02--93.43-0.6851-0.68510.04930.52640.0722--1.6480,944.00-97.62-95.67-94.18-96.5895.6676.98-1,351.64-1,612.76---175.330.00---11.43-12.198.31------
Fortress Biotech Inc85.11m-62.86m39.50m186.00--1.48--0.464-6.65-6.657.961.190.39762.274.55457,602.20-64.47-52.50-107.85-99.4668.2563.17-162.17-236.941.21-10.181.07--11.5825.7527.42---9.37--
Qilian International Holding Group Ltd46.47m-7.78m40.25m298.00--0.9407--0.8662-1.09-1.096.505.980.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Ocuphire Pharma Inc19.01m-11.30m40.96m14.00--0.8606--2.15-0.4867-0.48670.83661.840.391--4.521,357,929.00-23.24-58.31-25.89-65.94-----59.44-137.92---7.800.00---52.20---155.83------
Eyenovia Inc8.78k-32.44m42.23m57.00--20.03--4,809.50-0.7448-0.74480.00020.03840.0003--0.008154.04-116.94-80.31-190.14-117.700.00---369,519.70-680.950.6645-16.030.8914------2.68--152.20--
Data as of Jul 03 2024. Currency figures normalised to NDT Pharmaceuticals Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.